Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
ConclusionsOur data demonstrate thatRAS mutations do not affect outcome in rego-treated patients as well as TFD/TPI-treated patients. Nevertheless, a trend toward a higher efficacy of rego inRAS-mutated (in particular codon 12, rareRAS mutations, and G12D) patients has been recorded. The rego-TFD/TPI sequence seems to be superior to the reverse sequence in patients carrying anRAS codon 12 mutation, although the impact of other factors as disease burden or performance status cannot be excluded. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
ConclusionsOsimertinib rechallenge after initial pneumonitis was associated with significantly higher recurrence rates than conventional EGFR-TKI rechallenge. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling
ConclusionsReal-world datasets from clinical panel testing revealed the genomic landscape in gastric cancer by subgroup. These findings provide insights for the current therapeutic strategies and future development of treatments in gastric cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - April 13, 2024 Category: Cancer & Oncology Source Type: research
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer
ConclusionsWe noted important differences in co-occurring GA inERBB2-altered (ECDmut+, KDmut+, amp+) versusERBB2wt UBC, as well as higher mean TMB and higher APOBEC mutational signature in theERBB2-altered groups. Our results can help refine future clinical trial designs and elucidate possible response and resistance mechanisms forERBB2-altered UBC. (Source: Targeted Oncology)
Source: Targeted Oncology - April 3, 2024 Category: Cancer & Oncology Source Type: research
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor
ConclusionsEGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone can be safely delivered in paediatric patients aged 2 –21 years with solid or CNS tumours harbouring EGFR expression. The discovery of EGFR expression in a high proportion of paediatric gliomas means that EGFR may be useful as a target for other treatment strategies. Targeted therapeutic-loaded EDVs may be worth exploring further for their role in st imulating an anti-tumour immune response.ClinicalTrials.gov IdentifierNCT02687386. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
ConclusionsIn this systematic review, data from RCTs showed that palbociclib was effective, well tolerated, and maintained QoL in older patients with HR+/HER2 − a/mBC. Palbociclib treatment in older patients in real-world settings was associated with similar clinical benefit as in RCTs.PROSPERO RegistrationCRD42023444195. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
ConclusionsA superior effect of EV on patient survival compared to re-challenging chemotherapy and continuing pembrolizumab beyond PD was observed in our real-world analysis, which is attributed to the durable DOR in EV treatment despite the similar ORR to re-challenging chemotherapy. (Source: Targeted Oncology)
Source: Targeted Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research
Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
(Source: Targeted Oncology)
Source: Targeted Oncology - March 20, 2024 Category: Cancer & Oncology Source Type: research
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
ConclusionsDespite the limitations of the evidence base, the numerous analyses conducted have consistently indicated positive outcomes for tepotinib versus the current standard of care. (Source: Targeted Oncology)
Source: Targeted Oncology - March 16, 2024 Category: Cancer & Oncology Source Type: research
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
ConclusionsThese findings suggest that the DTX + RAM combination is an effective second-line therapy for older patients with advanced or recurrent NSCLC, offering favorable efficacy without treatment discontinuation owing to adverse events. (Source: Targeted Oncology)
Source: Targeted Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research
Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
ConclusionsNewly diagnosed AML patients withAML1/ETO fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients withAML1/ETO-positive AML, IC should be preferred over VEN/HM. (Source: Targeted Oncology)
Source: Targeted Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review
Conclusion and relevanceOur paper evaluated the effectiveness of lenvatinib for its FDA-approved indications; however, expansion of clinical trials into novel indications was characterized by diminished efficacy, while patients experienced a high burden of adverse events consistent with lenvatinib ’s established safety profile. Furthermore, clinical trials testing in novel indications was marked by repeated phase I and II clinical trials along with a failure to progress to phase III clinical trials. Future clinical trials using lenvatinib as an intervention should carefully evaluate the pot ential benefits and burden pat...
Source: Targeted Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
AbstractThis is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor shrinkage, and is an effective treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The ADAURA study assessed the effects of osimertinib versus placebo in patients with EGFR-mutated (exon 19 deletion or L858R) early stage (IB–IIIA) NSCLC removed by surgery (resected). Previous results from ADAURA demonstrated that patients treated with osimertinib stayed alive an...
Source: Targeted Oncology - March 11, 2024 Category: Cancer & Oncology Source Type: research
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia —A Podcast
AbstractOlder patients with acute lymphoblastic leukemia (ALL) have historically had poor outcomes (5-year survival rate, 20%) with standard intensive and dose-adjusted chemotherapy regimens, due to a high incidence of adverse biologic features including high-risk cytogenetics, presence ofTP53 mutations, and poor tolerance to intensive therapy. Thus, there is an unmet medical need in this patient population. Inotuzumab ozogamicin is a humanized antibody –drug conjugate that targets CD22-positive leukemic blasts. It is approved for the treatment of relapsed or refractory ALL and has been shown to be effective and tolerabl...
Source: Targeted Oncology - March 8, 2024 Category: Cancer & Oncology Source Type: research
Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2 − Breast Cancer
AbstractSacituzumab govitecan (TRODELVY®) is a first-in-class trophoblast cell-surface antigen 2 (Trop-2) –directed antibody and topoisomerase I inhibitor conjugate that is approved globally as monotherapy for the treatment of adults with unresectable locally advanced or metastatic, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−; defined as immunohistochem istry 0, 1+ or 2+ and in situ hybridization-negative) breast cancer who have received endocrine-based therapy and ≥ 2 additional systemic therapies in the advanced setting. In the phase III TROPiCS-02 trial, intravenous...
Source: Targeted Oncology - March 6, 2024 Category: Cancer & Oncology Source Type: research
